Patient Preparation

  • Clare Ockwell
  • Shirley SummersEmail author
Part of the Clinicians’ Guides to Radionuclide Hybrid Imaging book series (CGRHI)


When performing a therapy PET/CT scan, efficient and effective communication between the various teams and the patient is essential. Each modality has its own specific patient preparation, and these need to be combined to ensure that both the PET scan and the CT scan are of the best diagnostic quality (or optimal image quality) for radiotherapy planning. Communication and planning is essential prior to the injection of the radioactive tracer used in PET/CT to minimise the patient’s anxiety and radiation dose to all staff members (Table 3.1).


Target Volume Patient Position Radioactive Tracer Radiotherapy Planning Patient Preparation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Ronald B, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJG, Kotzerke J, Hoekstra OS, Pruim J, Marsden PK, Tatsch K, Hoekstra CJ, Visser EP, Arends B, Verzijlbergen FJ, Zijlstra JM, Comans EFI, Lammertsma AA, Paans AM, Willemsen AT, Beyer T, Bockisch A, Schaefer-Prokop C, Delbeke D, Baum RP, Chiti A, Krause BJ. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37(1):181–200.CrossRefGoogle Scholar
  2. 2.
    The Royal College of Radiologists. Standards for intravascular contrast agent administration to adult patients. 2nd ed. London: Royal College of Radiologists; 2010.Google Scholar
  3. 3.
    Haubner R. PET radiopharmaceuticals in radiation treatment planning—synthesis and biological characteristics. Radiother Oncol. 2010;96:280–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Nuñez R, Macapinlac HA, Yeung HW, Akhurst T, Cai S, Osman I, Gonen M, Riedel E, Scher HI, Larson SM. Combined 18F-FDG and 11C-Methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med. 2002;43(1):46–55.PubMedGoogle Scholar
  5. 5.
    Schnell O, Krebs B, Carlsen J, Miederer I, Goetz C, Goldbrunner RH, Wester H-J, Haubner R, Pöpperl G, Holtmannspötter M, Kretzschmar HA, Kessler H, Tonn J-C, Schwaiger M, Beer AJ. Imaging of integrin αvβ3 expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol. 2009;11(6):861–70.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Taïeb D, Timmers HJ, Hindié E, Guillet BA, Neumann HP, Walz MK, Opocher G, de Herder WW, Boedeker CC, de Krijger RR, Chiti A, Al-Nahhas A, Pacak K, Rubello D. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2012;39:1977–95.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Department of RadiotherapyThe Royal Marsden NHS Foundation TrustLondonUK
  2. 2.Nuclear Medicine and PET/CT DepartmentThe Royal Marsden NHS Foundation TrustLondonUK

Personalised recommendations